Conference Coverage

Patient-reported outcomes show impairment decades after acute knee injury


 

REPORTING FROM OARSI 2018


The average age of participants at follow-up was 59 years (range, 47-74 years); 30% were female. 58% of all patients had been treated non-surgically initially, and 38% remained non-surgically treated at the longterm follow-up. At baseline, 58% had a meniscus injury.

Compared with an age- and sex-matched Swedish population, patients with ACL injuries had a lower KOOS for pain, sport/recreational activities, and quality of life. For example, KOOS for knee pain was around 65-70 for those with prior ACL injuries, compared with 80-90 for those without ACL injuries, where 100 indicates the best outcome or least pain and zero the worst.

KOOS was not affected by whether or not patients had initial ACL surgery or surgery at any point in their follow up. It also did not appear to matter if patients had a meniscal injury at baseline or not.

Quadriceps and hamstring strength at the 3-7 year postinjury assessment did not affect the longterm KOOS, but the ability to hop on one leg did: Those who were not able to hop on one leg for more than 90% of the time on the unaffected limb at the 3-7 years follow-up had worse pain, symptoms, function, and quality of life at the longterm follow-up point.

Pages

Recommended Reading

Evidence builds for long-term ineffectiveness of steroid shots for knee OA
MDedge Internal Medicine
Sprifermin shows cartilage-building potential in knee OA patients
MDedge Internal Medicine
Arthritis treatment costs per person held steady from 2008 to 2014
MDedge Internal Medicine
Turmeric-, frankincense-derived supplement shows OA benefit
MDedge Internal Medicine
Experts review the year in rheumatology ... and what lies ahead
MDedge Internal Medicine
Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Internal Medicine
Intramuscular steroid injection reduced hip OA pain up to 12 weeks
MDedge Internal Medicine
Arthritis limits physical activity the most in the South
MDedge Internal Medicine
FDA advisory committee votes to recommend update to celecoxib safety labeling
MDedge Internal Medicine
Targeting inactivity, mood, and cognition could be key to reducing OA mortality
MDedge Internal Medicine